Dr. Tolba on Targeting NRG1 Fusions in NSCLC

Khaled A. Tolba MD, MBBCh
Published: Monday, Sep 09, 2019



Khaled A. Tolba MD, MBBCh, assistant professor of medicine, School of Medicine, Oregon Health & Science University, provides data from a study on targeting NRG1 fusions in non–small cell lung cancer (NSCLC).

Recently presented during the 2019 World Conference on Lung Cancer, Tolba’s research shows that afatinib (Gilotrif) has activity in NRG1-fusion positive NSCLC. This adds to other research, however, a study with a larger cohort is suggested for the future.

<<< 2019 World Conference on Lung Cancer
SELECTED
LANGUAGE


Khaled A. Tolba MD, MBBCh, assistant professor of medicine, School of Medicine, Oregon Health & Science University, provides data from a study on targeting NRG1 fusions in non–small cell lung cancer (NSCLC).

Recently presented during the 2019 World Conference on Lung Cancer, Tolba’s research shows that afatinib (Gilotrif) has activity in NRG1-fusion positive NSCLC. This adds to other research, however, a study with a larger cohort is suggested for the future.

<<< 2019 World Conference on Lung Cancer

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x